Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cardiovascular Translational Research
Published in: Journal of Cardiovascular Translational Research 6/2010

01-12-2010

The Paracrine Effect: Pivotal Mechanism in Cell-Based Cardiac Repair

Authors: Simon Maltais, Jacques P. Tremblay, Louis P. Perrault, Hung Q. Ly

Published in: Journal of Cardiovascular Translational Research | Issue 6/2010

Login to get access

Abstract

Cardiac cell therapy has emerged as a controversial yet promising therapeutic strategy. Both experimental data and clinical applications in this field have shown modest but tangible benefits on cardiac structure and function and underscore that transplanted stem–progenitor cells can attenuate the postinfarct microenvironment. The paracrine factors secreted by these cells represent a pivotal mechanism underlying the benefits of cell-mediated cardiac repair. This article reviews key studies behind the paracrine effect related to the cardiac reparative effects of cardiac cell therapy.
Literature
1.
Antman, E. M., Hand, M., Armstrong, P. W., Bates, E. R., Green, L. A., et al. (2008). 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation, 117, 296–329.PubMedCrossRef
2.
Jessup, M., & Brozena, S. (2003). Heart failure. The New England Journal of Medicine, 348, 2007–2018.PubMedCrossRef
3.
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., et al. (2005). ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation, 112, e154–e235.PubMedCrossRef
4.
Dimmeler, S., Zeiher, A. M., & Schneider, M. D. (2005). Unchain my heart: The scientific foundations of cardiac repair. Journal of Clinical Investigation, 115, 572–583.PubMed
5.
6.
7.
Hristov, M., & Weber, C. (2006). The therapeutic potential of progenitor cells in ischemic heart disease—past, present and future. Basic Research in Cardiology, 101, 1–7.PubMedCrossRef
8.
Leri, A., Kajstura, J., & Anversa, P. (2005). Cardiac stem cells and mechanisms of myocardial regeneration. Physiological Reviews, 85, 1373–1416.PubMedCrossRef
9.
Fraser, J. K., Schreiber, R. E., Zuk, P. A., & Hedrick, M. H. (2004). Adult stem cell therapy for the heart. The International Journal of Biochemistry & Cell Biology, 36, 658–666.CrossRef
10.
Muller, P., Beltrami, A. P., Cesselli, D., Pfeiffer, P., Kazakov, A., et al. (2005). Myocardial regeneration by endogenous adult progenitor cells. Journal of Molecular and Cellular Cardiology, 39, 377–387.PubMedCrossRef
11.
Caplice, N. M., Gersh, B. J., & Alegria, J. R. (2005). Cell therapy for cardiovascular disease: What cells, what diseases and for whom? Nature Clinical Practice. Cardiovascular Medicine, 2, 37–43.PubMedCrossRef
12.
Fukuda, K., & Yuasa, S. (2006). Stem cells as a source of regenerative cardiomyocytes. Circulation Research, 98, 1002–1013.PubMedCrossRef
13.
Gepstein, L. (2006). Cardiovascular therapeutic aspects of cell therapy and stem cells. Annals of the New York Academy of Sciences, 1080, 415–425.PubMedCrossRef
14.
Anversa, P., Kajstura, J., Leri, A., & Bolli, R. (2006). Life and death of cardiac stem cells: A paradigm shift in cardiac biology. Circulation, 113, 1451–1463.PubMedCrossRef
15.
Wang, Q. D., & Sjoquist, P. O. (2006). Myocardial regeneration with stem cells: Pharmacological possibilities for efficacy enhancement. Pharmacological Research, 53, 331–340.PubMedCrossRef
16.
Beltrami, A. P., Urbanek, K., Kajstura, J., Yan, S. M., Finato, N., et al. (2001). Evidence that human cardiac myocytes divide after myocardial infarction. The New England Journal of Medicine, 344, 1750–1757.PubMedCrossRef
17.
Beltrami, A. P., Barlucchi, L., Torella, D., Baker, M., Limana, F., et al. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 114, 763–776.PubMedCrossRef
18.
Oh, H., Bradfute, S. B., Gallardo, T. D., Nakamura, T., Gaussin, V., et al. (2003). Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. Proceedings of the National Academy of Sciences of the United States of America, 100, 12313–12318.PubMedCrossRef
19.
Matsuura, K., Nagai, T., Nishigaki, N., Oyama, T., Nishi, J., et al. (2004). Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. The Journal of Biological Chemistry, 279, 11384–11391.PubMedCrossRef
20.
Martin, C. M., Meeson, A. P., Robertson, S. M., Hawke, T. J., Richardson, J. A., et al. (2004). Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Developmental Biology, 265, 262–275.PubMedCrossRef
21.
Pfister, O., Mouquet, F., Jain, M., Summer, R., Helmes, M., et al. (2005). CD31− but not CD31+ cardiac side population cells exhibit functional cardiomyogenic differentiation. Circulation Research, 97, 52–61.PubMedCrossRef
22.
Lipinski, M. J., Biondi-Zoccai, G. G., Abbate, A., Khianey, R., Sheiban, I., et al. (2007). Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: A collaborative systematic review and meta-analysis of controlled clinical trials. Journal of the American College of Cardiology, 50, 1761–1767.PubMedCrossRef
23.
Abdel-Latif, A., Bolli, R., Tleyjeh, I. M., Montori, V. M., Perin, E. C., et al. (2007). Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Archives of Internal Medicine, 167, 989–997.PubMedCrossRef
24.
Schachinger, V., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., et al. (2006). Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: Final 1-year results of the REPAIR-AMI trial. European Heart Journal, 28, 638.
25.
Wollert, K. C., Meyer, G. P., Lotz, J., Ringes-Lichtenberg, S., Lippolt, P., et al. (2004). Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet, 364, 141–148.PubMedCrossRef
26.
Janssens, S., Dubois, C., Bogaert, J., Theunissen, K., Deroose, C., et al. (2006). Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: Double-blind, randomised controlled trial. Lancet, 367, 113–121.PubMedCrossRef
27.
Oettgen, P., Boyle, A. J., Schulman, S. P., & Hare, J. M. (2006). Controversies in cardiovascular medicine. Circulation, 114, 353–358.PubMedCrossRef
28.
Murry, C. E., Field, L. J., & Menasche, P. (2005). Cell-based cardiac repair: Reflections at the 10-year point. Circulation, 112, 3174–3183.PubMedCrossRef
29.
Boyle, A. J., Schulman, S. P., Hare, J. M., & Oettgen, P. (2006). Controversies in cardiovascular medicine: Ready for the next step. Circulation, 114, 339–352.PubMedCrossRef
30.
Charwat, S., Gyongyosi, M., Lang, I., Graf, S., Beran, G., et al. (2008). Role of adult bone marrow stem cells in the repair of ischemic myocardium: Current state of the art. Experimental Hematology, 36, 672–680.PubMedCrossRef
31.
Burt, R. K., Loh, Y., Pearce, W., Beohar, N., Barr, W. G., et al. (2008). Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA, 299, 925–936.PubMedCrossRef
32.
Sussman, M. A., & Murry, C. E. (2008). Bones of contention: Marrow-derived cells in myocardial regeneration. Journal of Molecular and Cellular Cardiology, 44, 950–953.PubMedCrossRef
33.
Rosenzweig, A. (2006). Cardiac cell therapy—mixed results from mixed cells. The New England Journal of Medicine, 355, 1274–1277.PubMedCrossRef
34.
Gersh, B. J., & Simari, R. D. (2006). Cardiac cell-repair therapy: Clinical issues. Nature Clinical Practice. Cardiovascular Medicine, 3(Suppl 1), S105–S109.PubMedCrossRef
35.
Murry, C. E., Reinecke, H., & Pabon, L. M. (2006). Regeneration gaps: Observations on stem cells and cardiac repair. Journal of the American College of Cardiology, 47, 1777–1785.PubMedCrossRef
36.
Ott, H. C., McCue, J., & Taylor, D. A. (2005). Cell-based cardiovascular repair—the hurdles and the opportunities. Basic Research in Cardiology, 100, 504–517.PubMedCrossRef
37.
Rosen, M. R. (2006). Are stem cells drugs? The regulation of stem cell research and development. Circulation, 114, 1992–2000.PubMedCrossRef
38.
Anversa, P., Leri, A., & Kajstura, J. (2006). Cardiac regeneration. Journal of the American College of Cardiology, 47, 1769–1776.PubMedCrossRef
39.
Hou, D., Youssef, E. A., Brinton, T. J., Zhang, P., Rogers, P., et al. (2005). Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: Implications for current clinical trials. Circulation, 112, I150–I156.PubMed
40.
Ly, H. Q., Hoshino, K., Pomerantseva, I., Kawase, Y., Yoneyama, R., et al. (2009). In vivo myocardial distribution of multipotent progenitor cells following intracoronary delivery in a swine model of myocardial infarction. European Heart Journal, 30, 2861–2868.PubMedCrossRef
41.
Schachinger, V., Aicher, A., Dobert, N., Rover, R., Diener, J., et al. (2008). Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation, 118, 1425–1432.PubMedCrossRef
42.
Hofmann, M., Wollert, K. C., Meyer, G. P., Menke, A., Arseniev, L., et al. (2005). Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation, 111, 2198–2202.PubMedCrossRef
43.
Beeres, S. L., Bengel, F. M., Bartunek, J., Atsma, D. E., Hill, J. M., et al. (2007). Role of imaging in cardiac stem cell therapy. Journal of the American College of Cardiology, 49, 1137–1148.PubMedCrossRef
44.
Yau, T. M., Kim, C., Li, G., Zhang, Y., Weisel, R. D., et al. (2005). Maximizing ventricular function with multimodal cell-based gene therapy. Circulation, 112, I123–I128.PubMedCrossRef
45.
Jain, M., DerSimonian, H., Brenner, D. A., Ngoy, S., Teller, P., et al. (2001). Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation, 103, 1920–1927.PubMed
46.
Lapidot, T., & Petit, I. (2002). Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Experimental Hematology, 30, 973–981.PubMedCrossRef
47.
Thum, T., Bauersachs, J., Poole-Wilson, P. A., Volk, H. D., & Anker, S. D. (2005). The dying stem cell hypothesis: Immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. Journal of the American College of Cardiology, 46, 1799–1802.PubMedCrossRef
48.
Heil, M., Ziegelhoeffer, T., Mees, B., & Schaper, W. (2004). A different outlook on the role of bone marrow stem cells in vascular growth: Bone marrow delivers software not hardware. Circulation Research, 94, 573–574.PubMedCrossRef
49.
Frangogiannis, N. G., Smith, C. W., & Entman, M. L. (2002). The inflammatory response in myocardial infarction. Cardiovascular Research, 53, 31–47.PubMedCrossRef
50.
Mann, D. L. (2002). Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circulation Research, 91, 988–998.PubMedCrossRef
51.
Riese, U., Brenner, S., Docke, W. D., Prosch, S., Reinke, P., et al. (2000). Catecholamines induce IL-10 release in patients suffering from acute myocardial infarction by transactivating its promoter in monocytic but not in T-cells. Molecular and Cellular Biochemistry, 212, 45–50.PubMedCrossRef
52.
Kranz, A., Rau, C., Kochs, M., & Waltenberger, J. (2000). Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. Journal of Molecular and Cellular Cardiology, 32, 65–72.PubMedCrossRef
53.
Ziegelhoeffer, T., Fernandez, B., Kostin, S., Heil, M., Voswinckel, R., et al. (2004). Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circulation Research, 94, 230–238.PubMedCrossRef
54.
Kinnaird, T., Stabile, E., Burnett, M. S., Shou, M., Lee, C. W., et al. (2004). Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation, 109, 1543–1549.PubMedCrossRef
55.
Kinnaird, T., Stabile, E., Burnett, M. S., Lee, C. W., Barr, S., et al. (2004). Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circulation Research, 94, 678–685.PubMedCrossRef
56.
Uemura, R., Xu, M., Ahmad, N., & Ashraf, M. (2006). Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circulation Research, 98, 1414–1421.PubMedCrossRef
57.
Gnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., et al. (2005). Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Natural Medicines, 11, 367–368.CrossRef
58.
Gnecchi, M., He, H., Noiseux, N., Liang, O. D., Zhang, L., et al. (2006). Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. The FASEB Journal, 20, 661–669.PubMedCrossRef
59.
Noiseux, N., Gnecchi, M., Lopez-Ilasaca, M., Zhang, L., Solomon, S. D., et al. (2006). Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Molecular Therapy, 14, 840–850.PubMedCrossRef
60.
Mirotsou, M., Zhang, Z., Deb, A., Zhang, L., Gnecchi, M., et al. (2007). Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proceedings of the National Academy of Sciences of the United States of America, 104, 1643–1648.PubMedCrossRef
61.
Fazel, S., Cimini, M., Chen, L., Li, S., Angoulvant, D., et al. (2006). Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. Journal of Clinical Investigation, 116, 1865–1877.PubMedCrossRef
62.
Brogi, E., Schatteman, G., Wu, T., Kim, E. A., Varticovski, L., et al. (1996). Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. Journal of Clinical Investigation, 97, 469–476.PubMedCrossRef
63.
Murtuza, B., Suzuki, K., Bou-Gharios, G., Beauchamp, J. R., Smolenski, R. T., et al. (2004). Transplantation of skeletal myoblasts secreting an IL-1 inhibitor modulates adverse remodeling in infarcted murine myocardium. Proceedings of the National Academy of Sciences of the United States of America, 101, 4216–4221.PubMedCrossRef
64.
Formigli, L., Perna, A. M., Meacci, E., Cinci, L., Margheri, M., et al. (2007). Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling. Journal of Cellular and Molecular Medicine, 11, 1087–1100.PubMedCrossRef
65.
Perez-Ilzarbe, M., Agbulut, O., Pelacho, B., Ciorba, C., San Jose-Eneriz, E., et al. (2008). Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. European Journal of Heart Failure, 10, 1065–1072.PubMedCrossRef
66.
Rehman, J., Traktuev, D., Li, J., Merfeld-Clauss, S., Temm-Grove, C. J., et al. (2004). Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation, 109, 1292–1298.PubMedCrossRef
67.
Lapidot, T., Dar, A., & Kollet, O. (2005). How do stem cells find their way home? Blood, 106, 1901–1910.PubMedCrossRef
68.
Tilling, L., Chowienczyk, P., & Clapp, B. (2009). Progenitors in motion: Mechanisms of mobilization of endothelial progenitor cells. British Journal of Clinical Pharmacology, 68, 484–492.PubMedCrossRef
69.
Tashiro, K., Tada, H., Heilker, R., Shirozu, M., Nakano, T., et al. (1993). Signal sequence trap: A cloning strategy for secreted proteins and type I membrane proteins. Science, 261, 600–603.PubMedCrossRef
70.
Levesque, J. P., Hendy, J., Takamatsu, Y., Simmons, P. J., & Bendall, L. J. (2003). Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. Journal of Clinical Investigation, 111, 187–196.PubMed
71.
De Falco, E., Porcelli, D., Torella, A. R., Straino, S., Iachininoto, M. G., et al. (2004). SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood, 104, 3472–3482.PubMedCrossRef
72.
Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., et al. (2006). A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. The Journal of Experimental Medicine, 203, 2201–2213.PubMedCrossRef
73.
Peichev, M., Naiyer, A. J., Pereira, D., Zhu, Z., Lane, W. J., et al. (2000). Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood, 95, 952–958.PubMed
74.
Ceradini, D. J., & Gurtner, G. C. (2005). Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends in Cardiovascular Medicine, 15, 57–63.PubMedCrossRef
75.
Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., et al. (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 109, 625–637.PubMedCrossRef
76.
Petit, I., Jin, D., & Rafii, S. (2007). The SDF-1-CXCR4 signaling pathway: A molecular hub modulating neo-angiogenesis. Trends in Immunology, 28, 299–307.PubMedCrossRef
77.
Massa, M., Rosti, V., Ferrario, M., Campanelli, R., Ramajoli, I., et al. (2005). Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood, 105, 199–206.PubMedCrossRef
78.
Isner, J. M. (2000). Tissue responses to ischemia: Local and remote responses for preserving perfusion of ischemic muscle. Journal of Clinical Investigation, 106, 615–619.PubMedCrossRef
79.
Tepper, O. M., Capla, J. M., Galiano, R. D., Ceradini, D. J., Callaghan, M. J., et al. (2005). Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood, 105, 1068–1077.PubMedCrossRef
80.
Minchenko, A., Salceda, S., Bauer, T., & Caro, J. (1994). Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cellular & Molecular Biology Research, 40, 35–39.
81.
Laterveer, L., Zijlmans, J. M., Lindley, I. J., Hamilton, M. S., Willemze, R., et al. (1996). Improved survival of lethally irradiated recipient mice transplanted with circulating progenitor cells mobilized by IL-8 after pretreatment with stem cell factor. Experimental Hematology, 24, 1387–1393.PubMed
82.
King, A. G., Horowitz, D., Dillon, S. B., Levin, R., Farese, A. M., et al. (2001). Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRObeta. Blood, 97, 1534–1542.PubMedCrossRef
83.
Discher, D. E., Mooney, D. J., & Zandstra, P. W. (2009). Growth factors, matrices, and forces combine and control stem cells. Science, 324, 1673–1677.PubMedCrossRef
84.
Yla-Herttuala, S., Rissanen, T. T., Vajanto, I., & Hartikainen, J. (2007). Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine. Journal of the American College of Cardiology, 49, 1015–1026.PubMedCrossRef
85.
Hattori, K., Dias, S., Heissig, B., Hackett, N. R., Lyden, D., et al. (2001). Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. The Journal of Experimental Medicine, 193, 1005–1014.PubMedCrossRef
86.
Hiasa, K., Egashira, K., Kitamoto, S., Ishibashi, M., Inoue, S., et al. (2004). Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor. Basic Research in Cardiology, 99, 165–172.PubMedCrossRef
87.
Laguens, R., Cabeza Meckert, P., Vera Janavel, G., Del Valle, H., Lascano, E., et al. (2002). Entrance in mitosis of adult cardiomyocytes in ischemic pig hearts after plasmid-mediated rhVEGF165 gene transfer. Gene Therapy, 9, 1676–1681.PubMedCrossRef
88.
Zarnegar, R., & Michalopoulos, G. K. (1995). The many faces of hepatocyte growth factor: From hepatopoiesis to hematopoiesis. The Journal of Cell Biology, 129, 1177–1180.PubMedCrossRef
89.
Nakamura, T., Mizuno, S., Matsumoto, K., Sawa, Y., & Matsuda, H. (2000). Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. Journal of Clinical Investigation, 106, 1511–1519.PubMedCrossRef
90.
Niagara, M. I., Haider, H., Jiang, S., & Ashraf, M. (2007). Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circulation Research, 100, 545–555.PubMedCrossRef
91.
Miyagawa, S., Sawa, Y., Taketani, S., Kawaguchi, N., Nakamura, T., et al. (2002). Myocardial regeneration therapy for heart failure: Hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation, 105, 2556–2561.PubMedCrossRef
92.
Duan, H. F., Wu, C. T., Wu, D. L., Lu, Y., Liu, H. J., et al. (2003). Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Molecular Therapy, 8, 467–474.PubMedCrossRef
93.
Urbanek, K., Torella, D., Sheikh, F., De Angelis, A., Nurzynska, D., et al. (2005). Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proceedings of the National Academy of Sciences of the United States of America, 102, 8692–8697.PubMedCrossRef
94.
Luster, A. D. (1998). Chemokines–chemotactic cytokines that mediate inflammation. The New England Journal of Medicine, 338, 436–445.PubMedCrossRef
95.
Murphy, P. M. (2001). Chemokines and the molecular basis of cancer metastasis. The New England Journal of Medicine, 345, 833–835.PubMedCrossRef
96.
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121, 335–348.PubMedCrossRef
97.
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., et al. (2003). Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL. Nature, 425, 307–311.PubMedCrossRef
98.
Schutyser, E., Su, Y., Yu, Y., Gouwy, M., Zaja-Milatovic, S., et al. (2007). Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. European Cytokine Network, 18, 59–70.PubMed
99.
Abbott, J. D., Huang, Y., Liu, D., Hickey, R., Krause, D. S., et al. (2004). Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation, 110, 3300–3305.PubMedCrossRef
100.
Askari, A. T., Unzek, S., Popovic, Z. B., Goldman, C. K., Forudi, F., et al. (2003). Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet, 362, 697–703.PubMedCrossRef
101.
Yamaguchi, J., Kusano, K. F., Masuo, O., Kawamoto, A., Silver, M., et al. (2003). Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation, 107, 1322–1328.PubMedCrossRef
102.
Heldin, C. H., Westermark, B., & Wasteson, A. (1981). Platelet-derived growth factor. Isolation by a large-scale procedure and analysis of subunit composition. Biochemical Journal, 193, 907–913.PubMed
103.
Raines, E. W., & Ross, R. (1982). Platelet-derived growth factor. I. High yield purification and evidence for multiple forms. Journal of Biological Chemistry, 257, 5154–5160.PubMed
104.
Raines, E. W. (2004). PDGF and cardiovascular disease. Cytokine & Growth Factor Reviews, 15, 237–254.CrossRef
105.
Sarzani, R., Arnaldi, G., & Chobanian, A. V. (1991). Hypertension-induced changes of platelet-derived growth factor receptor expression in rat aorta and heart. Hypertension, 17, 888–895.PubMed
106.
Edelberg, J. M., Lee, S. H., Kaur, M., Tang, L., Feirt, N. M., et al. (2002). Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: Feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation, 105, 608–613.PubMedCrossRef
107.
Zheng, J., Shin, J. H., Xaymardan, M., Chin, A., Duignan, I., et al. (2004). Platelet-derived growth factor improves cardiac function in a rodent myocardial infarction model. Coronary Artery Disease, 15, 59–64.PubMedCrossRef
108.
Xaymardan, M., Tang, L., Zagreda, L., Pallante, B., Zheng, J., et al. (2004). Platelet-derived growth factor-AB promotes the generation of adult bone marrow-derived cardiac myocytes. Circulation Research, 94, E39–E45.PubMedCrossRef
109.
Hao, X., Mansson-Broberg, A., Blomberg, P., Dellgren, G., Siddiqui, A. J., et al. (2004). Angiogenic and cardiac functional effects of dual gene transfer of VEGF-A165 and PDGF-BB after myocardial infarction. Biochemical and Biophysical Research Communications, 322, 292–296.PubMedCrossRef
110.
Hao, X., Mansson-Broberg, A., Gustafsson, T., Grinnemo, K. H., Blomberg, P., et al. (2004). Angiogenic effects of dual gene transfer of bFGF and PDGF-BB after myocardial infarction. Biochemical and Biophysical Research Communications, 315, 1058–1063.PubMedCrossRef
111.
Schweigerer, L., Neufeld, G., Friedman, J., Abraham, J. A., Fiddes, J. C., et al. (1987). Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature, 325, 257–259.PubMedCrossRef
112.
Schumacher, B., Pecher, P., von Specht, B. U., & Stegmann, T. (1998). Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease. Circulation, 97, 645–650.PubMed
113.
Henry, T. D., Grines, C. L., Watkins, M. W., Dib, N., Barbeau, G., et al. (2007). Effects of Ad5FGF-4 in patients with angina: An analysis of pooled data from the AGENT-3 and AGENT-4 trials. Journal of the American College of Cardiology, 50, 1038–1046.PubMedCrossRef
114.
Lu, H., Xu, X., Zhang, M., Cao, R., Brakenhielm, E., et al. (2007). Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proceedings of the National Academy of Sciences of the United States of America, 104, 12140–12145.PubMedCrossRef
115.
Padua, R. R., & Kardami, E. (1993). Increased basic fibroblast growth factor (bFGF) accumulation and distinct patterns of localization in isoproterenol-induced cardiomyocyte injury. Growth Factors, 8, 291–306.PubMedCrossRef
116.
Kardami, E. (1990). Stimulation and inhibition of cardiac myocyte proliferation in vitro. Molecular and Cellular Biochemistry, 92, 129–135.PubMedCrossRef
117.
Sakakibara, Y., Nishimura, K., Tambara, K., Yamamoto, M., Lu, F., et al. (2002). Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation. The Journal of Thoracic and Cardiovascular Surgery, 124, 50–56.PubMedCrossRef
118.
Baker, J., Liu, J. P., Robertson, E. J., & Efstratiadis, A. (1993). Role of insulin-like growth factors in embryonic and postnatal growth. Cell, 75, 73–82.PubMed
119.
Le Roith, D. (1997). Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. New England Journal of Medicine, 336, 633–640.PubMedCrossRef
120.
Werner, H., & Le Roith, D. (1997). The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Critical Reviews in Oncogenesis, 8, 71–92.PubMed
121.
Ishii, D. N., & Lupien, S. B. (1995). Insulin-like growth factors protect against diabetic neuropathy: Effects on sensory nerve regeneration in rats. Journal of Neuroscience Research, 40, 138–144.PubMedCrossRef
122.
Arsenijevic, Y., Weiss, S., Schneider, B., & Aebischer, P. (2001). Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2. The Journal of Neuroscience, 21, 7194–7202.PubMed
123.
de Pablo, F., & de la Rosa, E. J. (1995). The developing CNS: A scenario for the action of proinsulin, insulin and insulin-like growth factors. Trends in Neurosciences, 18, 143–150.PubMedCrossRef
124.
Urbanek, K., Rota, M., Cascapera, S., Bearzi, C., Nascimbene, A., et al. (2005). Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circulation Research, 97, 663–673.PubMedCrossRef
125.
Border, W. A., & Noble, N. A. (1994). Transforming growth factor beta in tissue fibrosis. The New England Journal of Medicine, 331, 1286–1292.PubMedCrossRef
126.
Blobe, G. C., Schiemann, W. P., & Lodish, H. F. (2000). Role of transforming growth factor beta in human disease. The New England Journal of Medicine, 342, 1350–1358.PubMedCrossRef
127.
Dickson, M. C., Martin, J. S., Cousins, F. M., Kulkarni, A. B., Karlsson, S., et al. (1995). Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development, 121, 1845–1854.PubMed
128.
Oshima, M., Oshima, H., & Taketo, M. M. (1996). TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Developmental Biology, 179, 297–302.PubMedCrossRef
129.
Burrows, F. J., Derbyshire, E. J., Tazzari, P. L., Amlot, P., Gazdar, A. F., et al. (1995). Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clinical Cancer Research, 1, 1623–1634.PubMed
130.
Bartram, U., Molin, D. G., Wisse, L. J., Mohamad, A., Sanford, L. P., et al. (2001). Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation, 103, 2745–2752.PubMed
131.
Goumans, M. J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P., et al. (2002). Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. The EMBO Journal, 21, 1743–1753.PubMedCrossRef
132.
Li, J., Hampton, T., Morgan, J. P., & Simons, M. (1997). Stretch-induced VEGF expression in the heart. Journal of Clinical Investigation, 100, 18–24.PubMedCrossRef
133.
Li, T. S., Hayashi, M., Ito, H., Furutani, A., Murata, T., et al. (2005). Regeneration of infarcted myocardium by intramyocardial implantation of ex vivo transforming growth factor-beta-preprogrammed bone marrow stem cells. Circulation, 111, 2438–2445.PubMedCrossRef
134.
Dimmeler, S., & Leri, A. (2008). Aging and disease as modifiers of efficacy of cell therapy. Circulation Research, 102, 1319–1330.PubMedCrossRef
135.
Valgimigli, M., Rigolin, G. M., Fucili, A., Porta, M. D., Soukhomovskaia, O., et al. (2004). CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation, 110, 1209–1212.PubMedCrossRef
136.
Seeger, F. H., Tonn, T., Krzossok, N., Zeiher, A. M., & Dimmeler, S. (2007). Cell isolation procedures matter: A comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. European Heart Journal, 28, 766–772.PubMedCrossRef
137.
Woo, Y. J., Panlilio, C. M., Cheng, R. K., Liao, G. P., Atluri, P., et al. (2006). Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation, 114, I206–I213.PubMedCrossRef
138.
Kuhn, B., del Monte, F., Hajjar, R. J., Chang, Y. S., Lebeche, D., et al. (2007). Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Natural Medicines, 13, 962–969.CrossRef
139.
Chien, K. R., Domian, I. J., & Parker, K. K. (2008). Cardiogenesis and the complex biology of regenerative cardiovascular medicine. Science, 322, 1494–1497.PubMedCrossRef
140.
Bursac, N. (2007). Stem cell therapies for heart disease: Why do we need bioengineers? IEEE Engineering in Medicine and Biology Magazine, 26, 76–79.PubMedCrossRef
Metadata
Title
The Paracrine Effect: Pivotal Mechanism in Cell-Based Cardiac Repair
Authors
Simon Maltais
Jacques P. Tremblay
Louis P. Perrault
Hung Q. Ly
Publication date
01-12-2010
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 6/2010
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-010-9198-2

Other articles of this Issue 6/2010

Journal of Cardiovascular Translational Research 6/2010 Go to the issue

OriginalPaper

Past, Present, and Future Regulatory Aspects of Ventricular Assist Devices

OriginalPaper

Hematologic Effects of Continuous Flow Left Ventricular Assist Devices

OriginalPaper

SDF-1-Enhanced Cardiogenesis Requires CXCR4 Induction in Pluripotent Stem Cells

OriginalPaper

Molecular Changes Occurring During Reverse Remodelling Following Left Ventricular Assist Device Support

OriginalPaper

Right Ventricular Failure—A Continuing Problem in Patients with Left Ventricular Assist Device Support

OriginalPaper

Clenbuterol Induces Cardiac Myocyte Hypertrophy via Paracrine Signalling and Fibroblast-derived IGF-1